Literature DB >> 1953004

Effect of controlled release salbutamol on nocturnal cough in asthma.

E W Hoskyns1, A Thomson, E Decker, A Hutchins, H Simpson.   

Abstract

Sixteen asthmatic children completed a double blind placebo controlled crossover study of controlled release salbutamol (CRS) to assess its efficacy in controlling night time cough. Children with asthma were enrolled into the study on the basis of a history of persistent cough confirmed by two overnight tape recordings at home. Outcome was measured by two overnight tapes on each medication. Other treatment was unaffected. There was no significant fall in cough counts on CRS. Median scores were 14.5 and 12.0 coughing episodes per night for CRS and placebo respectively. Mean overnight oxygen saturation was identical in both treatment periods but morning peak flow showed a trend towards improvement on CRS. Treatment with CRS does not have a significant effect in control of night cough although it may improve objective measurements of lung function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1953004      PMCID: PMC1793508          DOI: 10.1136/adc.66.10.1209

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

1.  Night cough counts and diary card scores in asthma.

Authors:  L N Archer; H Simpson
Journal:  Arch Dis Child       Date:  1985-05       Impact factor: 3.791

2.  Nocturnal asthma and urinary adrenaline and noradrenaline excretion.

Authors:  C A Soutar; M Carruthers; C A Pickering
Journal:  Thorax       Date:  1977-12       Impact factor: 9.139

3.  Nocturnal cough in asthma.

Authors:  A H Thomson; C Pratt; H Simpson
Journal:  Arch Dis Child       Date:  1987-10       Impact factor: 3.791

4.  Controlled release salbutamol tablets versus aminophylline in the control of reversible airways obstruction.

Authors:  T W Higenbottam; M A Khan; D O Williams; J R Mikhail; M D Peake; J Hughes
Journal:  J Int Med Res       Date:  1989 Sep-Oct       Impact factor: 1.671

5.  Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; M K Charter; J B Palmer; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  5 in total
  4 in total

Review 1.  Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?

Authors:  T D Holimon; C C Chafin; T H Self
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Persistent nocturnal cough: randomised controlled trial of high dose inhaled corticosteroid.

Authors:  M J Davies; P Fuller; A Picciotto; S A McKenzie
Journal:  Arch Dis Child       Date:  1999-07       Impact factor: 3.791

3.  Use of budesonide in severe asthmatics aged 1-3 years.

Authors:  G J Connett; C Warde; E Wooler; W Lenney
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

4.  Tools for assessing outcomes in studies of chronic cough: CHEST guideline and expert panel report.

Authors:  Louis-Philippe Boulet; Remy R Coeytaux; Douglas C McCrory; Cynthia T French; Anne B Chang; Surinder S Birring; Jaclyn Smith; Rebecca L Diekemper; Bruce Rubin; Richard S Irwin
Journal:  Chest       Date:  2015-03       Impact factor: 9.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.